Idioma:

Frequency and Risk Factors Associated With Osteonecrosis of the Jaw in Cancer Patients Treated With Intravenous Bisphosphonates

Hoff, Ana O ; Toth, Béla B ; Altundag, Kadri ; Johnson, Marcella M ; Warneke, Carla L ; Hu, Mimi ; Nooka, Ajay ; Sayegh, Gilbert ; Guarneri, Valentina ; Desrouleaux, Kimberly ; Cui, Jeffrey ; Adamus, Andrea ; Gagel, Robert F ; Hortobagyi, Gabriel N

Journal of bone and mineral research, 2008-06, Vol.23 (6), p.826-836 [Revista revisada por pares]

Washington, DC: John Wiley and Sons and The American Society for Bone and Mineral Research (ASBMR)

Texto completo disponible

Citas Citado por

Acciones

Título:
Frequency and Risk Factors Associated With Osteonecrosis of the Jaw in Cancer Patients Treated With Intravenous Bisphosphonates
Autor: Hoff, Ana O ; Toth, Béla B ; Altundag, Kadri ; Johnson, Marcella M ; Warneke, Carla L ; Hu, Mimi ; Nooka, Ajay ; Sayegh, Gilbert ; Guarneri, Valentina ; Desrouleaux, Kimberly ; Cui, Jeffrey ; Adamus, Andrea ; Gagel, Robert F ; Hortobagyi, Gabriel N
Materias: Adolescent ; Adult ; Aged ; Aged, 80 and over ; Biological and medical sciences ; bisphosphonates ; bone metastasis ; breast cancer ; Breast Neoplasms - drug therapy ; Breast Neoplasms - epidemiology ; Child ; Child, Preschool ; Diphosphonates - administration & dosage ; Diphosphonates - adverse effects ; Diphosphonates - therapeutic use ; Female ; Fundamental and applied biological sciences. Psychology ; Humans ; Infusions, Intravenous ; Jaw Neoplasms - drug therapy ; Jaw Neoplasms - epidemiology ; Male ; Middle Aged ; multiple myeloma ; Multiple Myeloma - drug therapy ; Multiple Myeloma - epidemiology ; Original ; Osteonecrosis - chemically induced ; Osteonecrosis - epidemiology ; osteonecrosis of the jaw ; osteoporosis ; Risk Factors ; Skeleton and joints ; Time Factors ; Vertebrates: osteoarticular system, musculoskeletal system
Es parte de: Journal of bone and mineral research, 2008-06, Vol.23 (6), p.826-836
Notas: Dr Gagel has served as a speaker and received research support from Novartis Pharmaceuticals. Drs Hortobagyi and Hoff received research support from Novartis Pharmaceuticals. All other authors state that they have no conflicts of interest.
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
Descripción: Introduction: Osteonecrosis of the jaw (ONJ) has been reported in patients treated with bisphosphonates. The incidence and risk factors associated with this disorder have not been clearly defined. Materials and Methods: We conducted a retrospective analysis of 4019 patients treated with intravenous bisphosphonates between 1996 and 2004. Our goals were to estimate the frequency, understand the clinical presentation, and identify risk factors associated with ONJ development. Results: Sixteen of 1338 patients with breast cancer (1.2%) and 13 of 548 patients with multiple myeloma (2.4%) developed ONJ. The median dose and duration of treatment with pamidronate or zoledronic acid were significantly higher in patients with ONJ (p < 0.0001). Multivariate Cox proportional hazards regression analysis identified treatment with zoledronic acid (hazards ratio [HR], 15.01; 95% CI: 2.41–93.48; p = 0.0037), treatment with pamidronate followed by zoledronic acid (HR, 4.00; 95% CI: 0.86–18.70; p = 0.078), and dental extractions (HR, 53.19; 95% CI: 18.20–155.46; p < 0.0001) as significant risks for ONJ in breast cancer. In multiple myeloma, dental extractions (HR, 9.78; 95% CI: 3.07–31.14; p = 0.0001) and osteoporosis (HR, 6.11; 95% CI: 1.56–23.98; p = 0.0095) were significant risk factors while controlling for bisphosphonate therapy. Thirteen of 29 patients were followed for a median of 17.1 mo (range, 7–67 mo); lesions healed in 3 patients during this period. Conclusions: ONJ is an uncommon but long‐lasting disorder that occurs mainly in breast cancer and multiple myeloma patients treated with intravenous bisphosphonates. High cumulative doses of bisphosphonates, poor oral health, and dental extractions may be significant risk factors for ONJ development. ONJ resolved in 23% of patients with conservative therapy.
Editor: Washington, DC: John Wiley and Sons and The American Society for Bone and Mineral Research (ASBMR)
Idioma: Inglés

Enlaces

Volver a la lista de resultados

Anterior Resultado 6 Siguiente Ir a la siguiente página

Realización: Logos de Redes Sociales:

Frequency and Risk Factors Associated With Osteonecrosis of the Jaw in Cancer Patients Treated With Intravenous Bisphosphonates

Hoff, Ana O ; Toth, Béla B ; Altundag, Kadri ; Johnson, Marcella M ; Warneke, Carla L ; Hu, Mimi ; Nooka, Ajay ; Sayegh, Gilbert ; Guarneri, Valentina ; Desrouleaux, Kimberly ; Cui, Jeffrey ; Adamus, Andrea ; Gagel, Robert F ; Hortobagyi, Gabriel N

Washington, DC: John Wiley and Sons and The American Society for Bone and Mineral Research (ASBMR)

Buscando en bases de datos remotas, por favor espere